A common variant at 8q24.21 is associated with renal cell cancer. by Gudmundsson, Julius et al.
ARTICLE
Received 5 Jul 2013 | Accepted 15 Oct 2013 | Published 13 Nov 2013
A common variant at 8q24.21 is associated
with renal cell cancer
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Renal cell carcinoma (RCC) represents between 80 and 90% of kidney cancers. Previous
genome-wide association studies of RCC have identiﬁed ﬁve variants conferring risk of the
disease. Here we report the results from a discovery RCC genome-wide association study and
replication analysis, including a total of 2,411 patients and 71,497 controls. One variant,
rs35252396[CG] located at 8q24.21, is signiﬁcantly associated with RCC after combining
discovery and replication results (OR¼ 1.27, Pcombined¼ 5.4 10 11) and has an average risk
allele frequency in controls of 46%. rs35252396[CG] does not have any strongly correlated
variants in the genome and is located within a region predicted to have regulatory functions in
several cell lines, including six originating from the kidney. This is the ﬁrst RCC variant
reported at 8q24.21 and it is largely independent (r2r0.02) of the numerous previously
reported cancer risk variants at this locus.
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E
stablished risk factors for renal cell carcinoma (RCC) are
smoking, obesity and hypertension. Risk of RCC has also
been shown to have a strong genetic component, both in
rare hereditary syndromes as well as in the general population1–3.
Rare, high-penetrance mutations accounting for syndromic RCC
have been found in several genes, including VHL, MET, FLCN
and FH4. Genome-wide association studies (GWAS) have
reported ﬁve sporadic RCC susceptibility loci5–7. However, in
combination, these risk variants account for only a small fraction
of the approximately twofold greater than the average risk of RCC
in ﬁrst-degree relatives of RCC patients1,2. Hence, it is likely to be
that several more such variants exist.
Here we report results from a RCC GWAS study of Icelandic
subjects. Our initial scan and replication study yields a common
variant at 8q24.21 associated with the disease. This variant does
not have any strongly correlated variants in the genome and is
located within a region predicted to have regulatory functions in
several cell lines, including six originating from the kidney.
Results
GWAS data and imputation in Icelandic samples. To search for
RCC risk variants, we analysed data generated by the ongoing
whole-genome sequencing project at deCODE genetics. The
variants discovered in the sequencing phase are propagated into
chip-genotyped individuals and into relatives of chip-genotyped
individuals, making use of the extensive genealogical information
available in Iceland and previously reported phasing and impu-
tation methods8. At the time that the association analysis in our
study was performed, 2,230 Icelanders had been sequenced to at
least tenfold coverage. The B38.5 million variants discovered
through whole-genome sequencing were imputed into 95,085
Icelanders who had all been genotyped using commercial
Illumina chips, as well as into 296,526 Icelanders without direct
chip genotypes but with family-based imputation genotype
information8,9 (see Methods). Our list of RCC patients contains
1,667 individuals diagnosed from 1955 until end of 2011, based
on the nationwide Icelandic Cancer Registry (ICR; http://
www.krabbameinsskra.is/indexen.jsp?icd=C64). The GWAS
association results presented here are based on the imputation
of 575 Icelandic patients who had been genotyped using one of
the commercial Illumina single-nucleotide polymorphism (SNP)
chips, as well as on 930 Icelandic patients who had at least partial
genotype data based on family-based imputation. As controls we
used imputed data from 67,725 individuals (25,875 had variants
imputed based on chip genotypes and 41,850 had variants
imputed with family-based methods) not diagnosed with RCC
according to the nationwide ICR. In the present RCC GWAS,
only variants with an imputed genotype information measure
value 40.9 were used (for a Q–Q plot, see Fig. 1).
Genetic association with RCC. According to our RCC GWAS
data set, association results for four5,6 of the ﬁve previously
reported GWAS-identiﬁed RCC susceptibility variants are
conﬁrmed (P between 0.011 and 3.0 10 4 for SNPs on 2p12,
11q13.3, 12p11.23 and 12q24.31 (Table 1) generated from logistic
regression analysis). Logistic regression is used throughout to test
for association between SNPs and disease. Results for the ﬁfth
variant, located on 2q22.3, are nonsigniﬁcant but the effect is in
the same direction as originally reported7 (P¼ 0.51, odds ratio
(OR)¼ 1.10).
The most signiﬁcant variant associated with RCC in our
GWAS was rs35252396[CG] located at 8q24.21 (OR¼ 1.30,
P¼ 1.8 10 7). This variant is a two base pair substitution, and
according to NCBI-dbSNP it is classiﬁed as a multiple nucleotide
variation with alleles of common length41, but it has also been
annotated as two consecutive single-nucleotide variations:
rs6470588(A/C) and rs6470589(C/G). Notably, rs6470588 is in
both the HapMap and the 1,000 Genome Project imputation
reference panels and it is also on most versions of the widely used
Illumina genome-wide genotyping chips.
No signiﬁcant difference was observed when the Icelandic
patients were stratiﬁed according to gender, age at diagnosis or
aggressiveness of the disease at the time of diagnosis (that is,
comparison of patients with stage T3 or higher, node-positive or
metastatic disease with the group of patients with stage T2 or
lower).
rs35252396 is located at 8q24.21 where numerous independent
variants have been shown to confer risk of both haemato-
logical and solid cancers but have not previously shown to confer
risk of RCC. rs35252396 is located 136Kb telomeric to MYC,
B13.5 Kb upstream of the non-protein coding gene PVT1
(according to the gene’s RefSeq NR_003367.2 coordinates;
Fig. 2). However, the PVT1 locus is complex and several mRNA
splice variants have been identiﬁed, some of which have a
transcription initiation site centromeric to rs35252396 (the
PVT1 locus is reviewed in Huppi et al.10). Of the previously
published cancer risk SNPs at 8q24, the one located closest to
rs35252396 is the urinary bladder cancer risk SNP rs9642880
(ref. 11). The correlation between these two variants is very
weak (r2¼ 0.015), and the correlations between the RCC risk
variant and other published cancer risk variants at 8q24 are
even weaker (Supplementary Table S1). No signiﬁcant association
was observed in our analysis between RCC and any of the
previously reported cancer risk variants at 8q24.
In addition to cancer risk variants, 8q24 has been reported to
contain variants, located intragenic in PVT1, associated with end-
stage renal disease in type 2 diabetics12. The strongest variant
(rs2648875) is very weakly correlated with the RCC variant
reported here (r2¼ 0.009) and rs2648875 is not associated with
RCC in our analysis.
We proceeded to validate the Icelandic RCC association results
for rs35252396 on 8q24 by genotyping it by using a single-track
assay in two RCC study groups of European descent coming from
the Netherlands and Spain. The results of the two study groups
showed signiﬁcant association (P¼ 5.9 10 5), and combining
them with the results from Iceland gave an estimated OR of 1.27
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Figure 1 | A Q–Q plot of the RCC GWAS results. The plot shows the
uncorrected (blue crosses) and corrected (using the method of genomic
control; red circles) w2-statistics from the RCC GWAS. This data set
consists of w2-values for 300,843 SNPs present on the Illumina chips used
to genotype the Icelandic study samples. The broken lines are boundaries of
the theoretical 95% point-wise conﬁdence band (assuming independent
w2-variables). The solid black equiangular line is displayed for reference
purposes.
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for rs35252396[CG] (Pcomb¼ 5.4 10 11; Table 2). A test of
heterogeneity of the ORs of all three study groups showed no
signiﬁcant difference (Phet¼ 0.67; Table 2). We also genotyped
rs35252396 in 1,678 Icelanders, using a single-track assay, to
conﬁrm the imputed Icelandic results. The correlation between
the imputed and measured genotypes was high (r¼ 0.98). As a
ﬁnal conﬁrmation, we Sanger sequenced 395 samples from the
three study populations and compared the results with the single-
variant genotyping results for rs35252396. The correlation
between these two data sets was also high (r¼ 0.97).
Table 1 | Association results for the Icelandic study population and variants at previously reported RCC GWAS loci.
Marker Locus Effect allele Other allele Effect allele
control frequency
OR (95% CI) P-value
rs7579899 2p21 A G 0.42 1.20 (1.09, 1.32) 3.0 104
rs12105918 2q22.3 C T 0.033 1.10 (0.83, 1.46) 0.51
rs7105934 11q13.3 A G 0.057 0.68 (0.54, 0.86) 1.3 10 3
rs718314 12p11.23 G A 0.27 1.16 (1.04, 1.30) 8.3 10 3
rs4765623 12q24.31 T C 0.33 1.14 (1.03, 1.26) 0.011
CI, conﬁdence interval; GWAS, genome-wide association study; OR, odds ratio; RCC, renal cell carcinoma; SNP, single-nucleotide polymorphism.
Logistic regression was used to test for association between SNPs and phenotype. All P-values shown are two-sided and have been adjusted using the method of genomic control. The reported OR with
95% CI is for the allele in the effect allele column. The results are based on the following number of Icelandic cases: 575 patients genotyped using one of the Illumina chips and 930 patients who have at
least partial genotype data based on family-based imputation. The 67,725 Icelandic controls used were genotyped accordingly: 25,875 were imputed based on chip genotypes and 41,850 were family-
based imputed.
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Figure 2 | Schematic view of the 8q24 region containing rs35252396 and several other disease risk variants. Shown are imputed association
results (blue circles) for variants with Po0.05 in the Icelandic RCC GWAS and located on 8q24.21 between 127.8Mb and 129.8Mb (Build 36). Logistic
regression was used to test for association between SNPs and phenotype. The red diamonds below the x axis denote the previously reported disease
risk variants at 8q24 in populations of European descent (1, rs12543663 (ref. 29); 2, rs10086908 (refs 29,30); 3, rs1016343 (ref. 29); 4, rs13252298
(ref. 29); 5, rs16901979 (ref. 31); 6, rs188140481 (ref. 32); 7, rs2456449 (ref. 33); 8, rs16902094 (ref. 34); 9, rs445114 (ref. 34)/rs620861 (refs 29,35);
10, rs6983267 (ref. 36); 11, rs1447295 (ref. 37); 12, rs13281615 (ref. 38); 13, rs9642880 (ref. 11); 14, rs2648875 (ref. 12); 15, rs2019960 (ref. 39); 16,
rs10088218 (ref. 40); see also Supplementary Table S1) and the black arrows represent genes in the region according to the RefSeq database (the
size of PVT1 is according to RefSeq NR_003367.2). The black traces represent the recombination rate based on results from the Utah residents of Northern
and Western European ancestry (CEU) HapMap population.
Table 2 | Summary association results for rs35252396 and RCC.
Study population Cases (n) Controls (n) Frequency OR (95% CI) P-value
Cases Controls
Iceland 1,505 67,725 0.56 0.50 1.30 (1.18, 1.44) 1.8 10 7
Spain 130 1,406 0.52 0.45 1.34 (1.03, 1.74) 0.027
The Netherlands 776 2,366 0.49 0.44 1.22 (1.09, 1.37) 6.5 104
All excl. Iceland 906 3,772 — 0.45 1.24 (1.12, 1.38) 5.9 10 5
All combined 2,411 71,497 — 0.46 1.27 (1.18, 1.37) 5.4 10 11
Phet¼0.67 I2¼0%
CI, conﬁdence interval; OR, odds ratio; RCC, renal cell carcinoma; SNP, single-nucleotide polymorphism.
Logistic regression was used to test for association between rs35252396[CG] and phenotype. All P-values shown are two-sided. Shown are the corresponding numbers of cases and controls (n), allelic
frequencies of variants in affected and control individuals, the allelic OR with 95% CI and P-value. Also shown are the P-values for the heterogeneity of the ORs (Phet) for all study groups, and I
2, which lies
between 0 and 100%, and describes the proportion of total variation in study estimates that is due to heterogeneity. For the combined study populations, the reported control frequency was the average,
unweighted control frequency of the individual populations, whereas the OR and the P-value were estimated using the Mantel–Haenszel model. The Icelandic association results are based on imputed
data for both cases and controls. The imputation of data for the Icelandic cases is done using 575 Icelandic patients who had been genotyped using one of the commercial Illumina SNP chips and 930
patients who had at least partial data based on family-based imputation. The imputation of data for the Icelandic controls was done using 25,875 Icelanders who were imputed based on chip genotypes
and 41,850 Icelanders who were family-based imputed. The Spanish and Dutch case–control samples were directly genotyped using single-track assay genotyping platform.
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When examining the ﬁt of the genotypes of rs35252396 to the
different models of inheritance, using only results generated by
single-variant assay genotyping from all three study populations,
the multiplicative model provided an adequate ﬁt. Because of the
high frequency of the risk allele of rs35252396, homozygous
carriers are B21% of the general population and they have an
estimated OR of 1.48 when compared with non-carriers (Table 3).
Interestingly, rs35252396 has no strongly correlated (r240.5)
variants, according to our analysis of the genomes of 2,230 whole-
genome-sequenced Icelanders and according to data from the
1,000 Genome Project. However, it has 33 variants that have high
D 0 (above 0.86) and an r2 between 0.2 and 0.5 (Supplementary
Table S2). Essentially, this means that other variants (mutations)
cannot be identiﬁed in our data set, which can fully account for
the observed association signal reported here.
Bioinformatic analysis of RCC risk variant. We cross referenced
the location of rs35252396 against potential biological functional
features according to the Encyclopedia of DNA Elements
project13. rs35252396 is located within a predicted DNaseI hot-
spot shown to have a strong signal strength in three renal cell lines
(RPTEC, HRE and HRCEpiC; Supplementary Fig. S1 and
Supplementary Table S3). We also noted, based on a FAIRE-Seq
analysis (Formaldehyde-Assisted Isolation of Regulatory Element),
that rs35252396 is located at a reported regulatory site in the renal
cell adenocarcinoma cell line RCC_7860. This site has also been
shown to bind KAP1 and ZNF263 transcription factors, according
to a ChIP-Seq analysis, in the embryonic kidney cell lines HEK293
and HEK293-T-Rex, respectively. Furthermore, rs35252396 is
located within a chromatin interaction site, predicted to interact
with the 50-untranslated region of MYC based on a ChIA-PET
assay analysis of the leukemia cell line k562 (Supplementary Fig.
S1 and Supplementary Table S4). Finally, the Ensembl Genome
Browser deﬁned rs35252396 as a regulatory region variant with a
biological function in several different cell lines. Whether any of
these observations sheds light on the association with RCC
remains to be shown.
Discussion
In summary, we have discovered a new RCC risk variant at the
8q24 locus, a locus shown to be associated with cancers in several
organs but not previously with kidney cancer. Interestingly, this
variant has no strongly correlated variants and it is located within
several potential regulatory regions of the genome. Otherwise, the
risk proﬁle of this new variant is comparable to other GWAS-
based discovered risk variants in being common and conferring
moderate risk of the disease. However, the discovery of each new
RCC risk variant may ultimately contribute to earlier detection
and better treatment of the disease.
Methods
Study populations. The Icelandic study population is based on a nationwide list
from the ICR containing 1,651 Icelandic RCC patients diagnosed from 1 January
1955, to 31 December 2011. The Icelandic RCC sample collection included 575
patients who were recruited from November 2000 until June 2012. A total of 1,505
patients were included in the current study, of which 575 had genotypes from a
genome-wide SNP genotyping effort, using the Inﬁnium II assay method and the
Sentrix HumanHap300 BeadChip (Illumina, San Diego, CA, USA), and 930 had
imputed genotypes based on genotypic information from ﬁrst- or second-degree
relatives who have been chip genotyped. In total, B10% of the RCC patients had
carcinomas of the papillary, chromophobe-mixed or unknown histological sub-
types. Of the 1,505 RCC patients, 14 were among the 2,230 individuals who had
been whole-genome sequenced. The mean age at diagnosis was 66 years for RCC
patients in our study.
The 67,725 control individuals (25,875 had variants imputed based on chip
genotypes and 41,850 had variants imputed with family-based methods) comprises
individuals recruited through different genetic research projects at deCODE. The
controls have been diagnosed with common diseases of the cardiovascular system
(for example, stroke or myocardial infraction), psychiatric and neurological
diseases (for example, schizophrenia and bipolar disorder), endocrine and auto-
immune system (for example, type 2 diabetes and asthma), malignant diseases
other than RCC and individuals randomly selected from the Icelandic genealogical
database. The controls had a mean age of 84 years and the range was from
8 to 105 years. The controls were absent from the nationwide list of RCC patients
according to the ICR.
The study was approved by the Data Protection Commission of Iceland and the
National Bioethics Committee of Iceland. Written informed consent was obtained
from all patients and controls. Personal identiﬁers associated with medical
information and blood samples were encrypted with a third-party encryption
system as previously described14.
The Dutch RCC sample series (N¼ 776) consist of a population-based series
(N¼ 427) and a hospital-based series (N¼ 349). The hospital-based series has been
described in a previous publication15. Patients with urological diseases were
recruited through the outpatient urology clinic of the Radboud University Medical
Center (RUMC) from January 1999 onwards. The B10,000 patients who
participated in this study gave informed consent for the study and for linking their
data with disease registries. The study was linked with the Dutch population-based
cancer registry to identify patients who were diagnosed with renal cell cancer.
Three hundred and forty-nine patients were identiﬁed.
The (non-overlapping) population-based series has been recruited in 2009.
Patients were identiﬁed through the population-based regional cancer registry held
by the Comprehensive Cancer Centre East, Nijmegen. Patients diagnosed between
1995 and 2008, o75 years of age, were selected, and their vital status and current
addresses updated through the hospital information systems of the seven
community hospitals and one university hospital (RUMC) that are covered by the
cancer registry. All patients still alive on 1 February 2009 were invited to the study
by the Comprehensive Cancer Center on behalf of the patients’ treating physicians.
In case of consent, patients were sent a lifestyle questionnaire to ﬁll out, and blood
samples were collected by Thrombosis Service centers that hold ofﬁces in all the
communities in the region. Seven hundred and eight patients were invited to
participate; 465 responded positively, and data and samples were collected from
427 patients. All the patients who were selected for analyses are of self-reported
European descent. Clinical data were obtained through the cancer registry. The
study protocol was approved by the Institutional Review Board of the Radboud
University Medical Centre (RUMC) and all study subjects gave written informed
consent.
The Dutch controls were recruited within a project entitled ‘Nijmegen Biomedical
Study’ (NBS). The details of this study were reported previously16. Brieﬂy, this is a
population-based survey conducted by the Department for Health Evidence and the
Department of Clinical Chemistry of the RUMC, in which 9,371 individuals
participated from a total of 22,500 age- and sex-stratiﬁed invitees, randomly selected
from the general population of the municipality of Nijmegen. Control individuals
from the NBS were invited to participate in a study on gene–environment
interactions in multifactorial diseases, such as cancer. The 2,366 controls are a
subsample of all the participants to the NBS and were cancer free at the date of
recruitment. All control subjects were fully informed about the goals and the
procedures of the study, and signed an informed consent form. The study protocols
of the NBS were approved by the Institutional Review Board of the RUMC.
The Spanish study population used in this study consisted of 130 pathologically
conﬁrmed RCC. The cases were recruited from the Oncology Department of
Zaragoza Hospital in Zaragoza, Spain, from June 2004 to September 2009. Clinical
information, including age at onset, grade and stage, was obtained from medical
Table 3 | Genotypic association results for rs35252396.
Genotypes counts (00/0X/XX) Heterozygous carriers (0X) Homozygous carriers (XX)
Cases Controls OR (95% CI) P-value OR (95% CI) P-value
369/726/407 1,477/2,421/1,031 1.17 (1.00–1.36) 0.045 1.48 (1.25–1.75) 3.9 106
CI, conﬁdence interval; OR, odds ratio; RCC, renal cell carcinoma.
Results are for the three study groups from Iceland, the Netherlands and Spain. Shown are the genotype counts and association results according to genotype status of cases and controls for rs35252396
generated by direct genotyping. The genotypes are as follows: rs35252396[AC]¼0 and rs35252396[CG]¼X. Mantel–Haenszel test was performed to calculate the combined OR and P-value.
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records. The average age at diagnosis for the patients was 63 years. The 1,406
Spanish control individuals were approached at the University Hospital in
Zaragoza and were cancer free at the time of recruitment. All study subjects were of
self-reported European descent and study protocols were approved by the
Institutional Review Board of Zaragoza University Hospital. All subjects gave
written informed consent.
Illumina genome-wide genotyping. The Icelandic chip-typed samples were
assayed with the Illumina Human Hap300, Hap CNV370, Hap 610, 1M or Omni-1
Quad bead chips at deCODE genetics. SNPs were excluded if they had yieldo95%,
minor allele frequency o1% in the population or signiﬁcant deviation from the
Hardy–Weinberg equilibrium in the controls (Po0.001), if they produced an
excessive inheritance error rate (40.001), or if there was substantial difference in
allele frequency between chip types (from just a single chip if that resolved all
differences, but from all chips otherwise). All samples with a call rate o97% were
excluded from the analysis. The ﬁnal set of SNPs used for long-range phasing
composed of 785,863 SNPs. We note that rs35252396(CG/AC) has also been
annotated as two consecutive single-nucleotide variations, rs6470588(A/C) and
rs6470589(C/G). rs6470588 is present on the Illumina chips used to genotype the
Icelandic sample.
Single-track assay SNP genotyping and Sanger sequencing. Genotyping of
rs35252396 as reported in Table 2 for patients and controls from the Netherlands
and Spain was carried out by deCODE genetics in Reykjavik, Iceland, applying the
Centaurus17 (Nanogen) single-track assay platform. To validate the imputed
Icelandic association results for rs35252396, we directly genotyped 1,678 Icelandic
study subjects using a single-track assay. The correlation (r) between the two
genotyping methods was 0.98.
For conﬁrming the genotypes from the single-track assay, we Sanger sequenced
395 individuals from Iceland, the Netherlands and Spain. The correlation between
these two data sets was high (r¼ 0.97).
Whole-genome sequencing and SNP genotype calling. Of the 2,230 individuals
whole-genome sequenced and used in the current study, 14 have been diagnosed
with RCC according to the nationwide list maintained by the ICR.
Paired-end libraries for sequencing were prepared according to the manu-
facturer’s instructions (Illumina). In short, B5 mg of genomic DNA, isolated from
frozen blood samples, were fragmented to a mean target size of 300 bp using a
Covaris E210 instrument. The resulting fragmented DNA was end repaired using
T4 and Klenow polymerases, and T4 polynucleotide kinase with 10mM dNTP,
followed by the addition of an ‘A’ base at the ends using Klenow exo fragment
(30 to 50-exo minus) and dATP (1mM). Sequencing adaptors containing ‘T’
overhangs were ligated to the DNA products followed by agarose (2%) gel
electrophoresis. Fragments of about 400 bp were isolated from the gels (QIAGEN
Gel Extraction Kit), and the adaptor-modiﬁed DNA fragments were PCR enriched
for ten cycles using Phusion DNA polymerase (Finnzymes Oy) and PCR primers
PE 1.0 and PE 2.0 (Illumina). Enriched libraries were further puriﬁed using agarose
(2%) gel electrophoresis as described above. The quality and concentration of the
libraries were assessed with the Agilent 2100 Bioanalyzer using the DNA 1000
LabChip (Agilent). Barcoded libraries were stored at  20 C. All steps in the
workﬂow were monitored using an in-house laboratory information management
system with barcode tracking of all samples and reagents.
Template DNA fragments were hybridized to the surface of ﬂow cells (Illumina
PE ﬂowcell, v4) and ampliﬁed to form clusters using the Illumina cBot. In brief,
DNA (3–10 pM) was denatured, followed by hybridization to grafted adaptors on
the ﬂowcell. Isothermal bridge ampliﬁcation using Phusion polymerase was then
followed by linearization of the bridged DNA, denaturation, blocking of 30-ends
and hybridization of the sequencing primer. Sequencing by synthesis was
performed on Illumina GAIIx instruments equipped with paired-end modules.
Paired-end libraries for whole-genome sequencing were sequenced using either
2 101 or 2 120 cycles of incorporation and imaging with Illumina sequencing
kits, v4 or v5 (TruSeq). Each library or sample was initially run on a single lane for
validation, followed by further sequencing of Z4 lanes with targeted raw cluster
densities of 500–700 kmm 2, depending on the version of the data imaging
and analysis packages. Imaging and analysis of the data was performed using
SCS2.6 /RTA1.6, SCS2.8/RTA1.8 or SCS2.9&RTA1.9 software packages from
Illumina, respectively. Real-time analysis involved conversion of image data to base
calling in real time.
Reads were aligned to NCBI Build 36 of the human reference sequence using
Burrows-Wheeler Aligner 0.5.9 (ref. 18). Alignments were merged into a single BAM
ﬁle and marked for duplicates using Picard 1.55 (http://picard.sourceforge.net/).
Only non-duplicate reads were used for the downstream analyses.
Variants were called using Genome Analysis Toolkit, (GenomeAnalysisTK)
1.2-29-g0acaf2d (ref. 19), by applying base quality score recalibration, INDEL
realignment and performing SNP and INDEL discovery and genotyping using
standard hard ﬁltering20. Variants were annotated using SNPeff and Genome
Analysis Toolkit 1.4-9-g1f1233b with only the highest-impact effect19. The allele
frequency used for ﬁltering was based on phased genotypes of 38.5 million SNPs
and INDELs from the 2,230 whole-genome-sequenced Icelanders.
Long-range phasing and genotype imputation. Long-range phasing of all chip-
genotyped individuals was performed with methods described previously8,21–24.
In brief, phasing is achieved using an iterative algorithm, which phases a single
proband at a time given the available phasing information about everyone else that
shares a long haplotype identically by state with the proband. Given the large
fraction of the Icelandic population that has been chip typed, accurate long-range
phasing is available genome wide for all chip-typed Icelanders.
We imputed the SNPs identiﬁed and genotyped through sequencing the whole
genomes of 2,230 Icelanders into the additional 92,855 Icelanders who had been
chip typed and phased with long-range phasing. These imputations are performed
based on long haplotype sharing based on the chip SNPs and were performed using
the same model as used by IMPUTE25. The genotype data from sequencing can be
ambiguous owing to low sequencing coverage. To phase the sequencing genotypes,
an iterative algorithm was applied for each SNP with alleles 0 and 1. We let H be
the long-range-phased haplotypes of the sequenced individuals and applied the
following algorithm:
For each haplotype h in H, use the hidden Markov model (HMM) of IMPUTE
to calculate for every other k in H, gh,k, (see details for calculating gh,k below). For
every h in H, initialize the parameter yh, which speciﬁes how likely the one allele of
the SNP is to occur on the background of h from the genotype likelihoods obtained
from sequencing. The genotype likelihood Lg is the probability of the observed
sequencing data at the SNP for a given individual assuming g is the true genotype
at the SNP. If L0, L1 and L2 are the likelihoods of the genotypes 0, 1 and 2 in the
individual that carries h, then set yh :
yh ¼ L2 þ
1
2 L1
L2 þ L1 þ L0 : ð1Þ
For every pair of haplotypes h and k in H that are carried by the same
individual, use the other haplotypes in H to predict the genotype of the SNP on the
backgrounds of h and k:
th ¼
X
l2H n fhg
gh;lyl ð2Þ
and
tk ¼
X
l2H n fkg
gk;lyl: ð3Þ
Combining these predictions with the genotype likelihoods from sequencing
gives un-normalized updated phased genotype probabilities:
P00 ¼ 1 thð Þ 1 tkð ÞL0; ð4Þ
P10 ¼ th 1 tkð Þ 12 L1; ð5Þ
P01 ¼ ð1 thÞtk 12 L1; ð6Þ
and
P11 ¼ thtkL2: ð7Þ
Now use these values to update yh and yk to:
yh ¼ P10 þP11P00 þ P01 þP10 þ P11 ð8Þ
and
yk ¼ P01 þ P11P00 þ P01 þ P10 þP11 : ð9Þ
Repeat step 3 when the maximum difference between iterations is greater than a
convergence threshold e. We used e¼ 10 7. Given the long-range-phased
haplotypes and y, the allele of the SNP on a new haplotype h not in H, is imputed
as
P
l2H gh;lyl .
The above algorithm can easily be extended to handle simple family structures
such as parent–offspring pairs and triads by letting the P distribution run over all
founder haplotypes in the family structure. The algorithm also extends trivially to
the X chromosome. If source genotype data are only ambiguous in phase, such as
chip genotype data, then the algorithm is still applied; however, all but one of the Ls
will be 0. In some instances, the reference set was intentionally enriched for carriers
of the minor allele of a rare SNP to improve imputation accuracy. In this case,
expected allele counts will be biased toward the minor allele of the SNP. Call the
enrichment of the minor allele E and let y0 be the expected minor allele count
calculated from the naive imputation method and let y be the unbiased expected
allele count, then:
y
0 ¼ Ey
1 yþ Ey ð10Þ
and hence,
y ¼ y
0
Eþð1 EÞy0 : ð11Þ
This adjustment was applied to all imputations based on enriched imputations
sets. We note that if y0 is 0 or 1, then y will also be 0 or 1, respectively.
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The coefﬁcients gh,k are calculated based on the same HMM model as that used
by IMPUTE. Given a haplotype h in H, gh,k are calculated simultaneously for all
k 2 H n fhg. Assuming that at each marker i the haplotype h has a common
ancestor with a haplotype in H n fhg and denote the variable indicating this with
the latent variable zi 2 H n fhg, the hidden variable in the HMM, then
gh;k;i ¼ P zi ¼ k jall markersð Þ: ð12Þ
Given the Markov assumtption of the HMM, the model is fully speciﬁed by
emission and transition probabilities.
We deﬁne the emission probabilities of the HMM at each marker i as:
Pðzi ¼ k jmarker iÞ ¼ 1 l; if h and k match at il; if h and k mismatch at i

ð13Þ
where l can be thought of as a penalty for a mismatch. We used l¼ 10 7 in our
implementation. We deﬁne the transmission probabilities of the HMM model as:
P zi j zi 1;markers 1; . . . ; i 1ð Þ ¼ e
 riN þ 1 e
ri
N
N ; if zi ¼ zi 1
1 e
ri
N
N ; if zi 6¼ zi 1
(
ð14Þ
where N is the number of haplotypes in k 2 H n fhg, which for autosomal
chromosomes is 2(2,230 1) here, and ri ¼ 4Neri , where ri is the genetic distance
between markers i 1 and i according to the most recent version of the
deCODE genetic map24 and Ne was originally meant to be an estimate of the
effective number of haplotypes in the population that our sample comes from,
we used Ne¼ 7,000. These deﬁnitions fully specify the probability distribution
Pðzi jall markersÞ. Calculating gh,k for a single haplotype requires O(MN)
operations, where N is the number of haplotypes and M is the number of markers.
As these calculations can be performed for one haplotype at a time, the calculations
can be parallelized across a computer cluster for efﬁciency. In practice, most
of the gh,k will be close to zero and can be safely ignored (we used a threshold
of 10 6 of the largest value at each marker for each h), greatly reducing
storage requirements. These calculations took B21 days on a cluster of 800
computing nodes.
In addition to imputing sequence variants from the whole-genome sequencing
effort into chip-genotyped individuals, we also performed a second imputation step
where genotypes were imputed into relatives of chip-genotyped individuals. The
inputs into the second imputation step are the fully phased (in particular, every
allele has been assigned a parent of origin) imputed and chip-type genotypes of the
available chip-typed individuals. The algorithm used to perform the second
imputation step consists of the following steps.
For each ungenotyped individual (the proband), ﬁnd all chip-genotyped
individuals within two meiosis of the individual. The six possible types of two
meiosis relatives of the proband are (ignoring more complicated relationships due
to pedigree loops) as follows: parents, full and half siblings, grandparents, children
and grandchildren. If all pedigree paths from the proband to a genotyped relative
go through other genotyped relatives, then that relative is excluded. For example, if
a parent of the proband is genotyped, then the proband’s grandparents through
that parent are excluded. If the number of meiosis in the pedigree around the
proband exceeds a threshold (we used 12), then relatives are removed from the
pedigree until the number of meiosis falls below 12, to reduce computational
complexity.
At every point in the genome, calculate the probability for each genotyped relative
sharing with the proband based on the autosomal SNPs used for phasing. A multi-
point algorithm based on the HMM Lander–Green multipoint linkage algorithm
using fast Fourier transforms is used to calculate these sharing probabilities26,27.
First, single point-sharing probabilities are calculated by dividing the genome into
0.5 cM bins and using the haplotypes over these bins as alleles. If there are n
informative haplotypes in the pedigree around the proband, it is denoted by v 2 Zn2 ,
the inheritance vector (sharing pattern)26. Haplotypes that are the same, except at
most at a single SNP, are treated as identical. Given the haplotype frequencies in each
bin, the single point distribution, P vjhaplotype datað Þðhaplotype data jvÞ, can
be calculated as in classical multipoint linkage analysis26. When the haplotypes
in the pedigree are incompatible over a bin, then a uniform probability distribution
was used for that bin,
P v j haplotype datað Þ ¼ 1
2n
: ð15Þ
The most common causes for such incompatibilities are recombination in
members belonging to the pedigree, phasing errors and genotyping errors. Note
that as the input genotypes are fully phased, the single point information is
substantially more informative than for unphased genotyped, in particular one
haplotype of the parent of a genotyped child is always known. The single point
distributions are then convolved using the multipoint algorithm to obtain
multipoint sharing probabilities at the centre of each bin just as in the original
Lander–Green algorithm26. Genetic distances were obtained from the most recent
version of the deCODE genetic map24.
On the sharing probabilities at the centre of each bin, all the SNPs from the
whole-genome sequencing are imputed into the proband. We now show how to
impute the genotype of the paternal allele of a SNP located at x, ﬂanked by bins
with centers at xleft and xright. Starting with the left bin, going through all possible
inheritance vectors v, let Iv be the set of haplotypes of genotyped individuals that
share identically by descent within the pedigree with the proband’s paternal
haplotype given the inheritance vector v and P(v) be the probability of v at the left
bin—this is the output from step 2 above—and let ei be the expected allele count of
the SNP for haplotype i. Then,
ev ¼
P
i2Iv eiP
i2Iv 1
ð16Þ
is the expected allele count of the paternal haplotype of the proband, given v, and
an overall estimate of the allele count, given the sharing distribution at the left bin,
is obtained from:
eleft¼
X
v
PðvÞev : ð17Þ
If Iv is empty, then no relative shares with the proband’s paternal haplotype
given v, and thus there is no information about the allele count. We therefore store
the probability that some genotyped relative shared the proband’s paternal
haplotype,
Oleft ¼
X
v;Iv¼+
PðvÞ ð18Þ
and an expected allele count, conditional on the proband’s paternal haplotype
being shared by at least one genotyped relative:
cleft ¼
P
v;Iv 6¼+
PðvÞevP
v;Iv 6¼+
PðvÞ : ð19Þ
In the same way, we calculated Oright and cright. Linear interpolation is then used
to get an estimates at the SNP from the two ﬂanking bins:
O ¼ Oleft þ x xleftxright  xlef t Oright Olef t
 
; ð20Þ
c ¼ cleft þ x xleftxright  xleft cright  cleft
 
: ð21Þ
If y is an estimate of the population frequency of the SNP then Ocþð1OÞy is an
estimate of the allele count for the proband’s paternal haplotype. Similarly, an
expected allele count can be obtained for the proband’s maternal haplotype.
The informativeness of genotype imputation was estimated by the ratio of the
variance of imputed expected allele counts and the variance of the actual allele
counts:
VarðE y jchip datað ÞÞ
VarðyÞ ; ð22Þ
where y 2 f0; 1g is the allele count. VarðE y jchip datað ÞÞ was estimated by the
observed variance of the imputed expected counts and VarðyÞ was estimated by
p(1 p), where p is the allele frequency. For the present study, when imputed
genotypes are used, the information value for all SNPs is 40.90. The imputed
genotype information measure value for rs35252396 is 0.99.
Case–control association testing. Logistic regression was used to test for asso-
ciation between SNPs and disease, treating disease status as the response and
expected genotype counts from imputation or allele counts from direct genotyping as
covariates. Testing was performed using the likelihood ratio statistic. When testing
for association based on the imputed genotypes, controls were matched to cases
based on the informativeness of the imputed genotypes, such that for each case C
controls of matching informativeness where chosen. Failing to match cases and
controls will lead to a highly inﬂated genomic control factor, and in some cases may
lead to spurious false-positive ﬁndings. The informativeness of each of the imputa-
tion of each one of an individual’s haplotypes was estimated by taking the average of
a e; yð Þ ¼
e y
1 y ; e  y
y e
y ; eoy

ð23Þ
over all SNPs imputed for the individual, where e is the expected allele count for the
haplotype at the SNP and y is the population frequency of the SNP. This measure
has the property that it is 0 if the population frequency is imputed, a y; yð Þ ¼ 0, and 1
if either allele is imputed with full certainty, a 0; yð Þ ¼ að1; yÞ ¼ 1. The mean
informativeness values cluster into groups corresponding to the most common
pedigree conﬁgurations used in the imputation, such as imputing from parent into
child or from child into parent. On the basis of this clustering of imputation
informativeness, we divided the haplotypes of individuals into 7 groups of varying
informativeness, which created 27 groups of individuals of similar imputation
informativeness, 7 groups of individuals with both haplotypes having similar
informativeness, 21 groups of individuals with the 2 haplotypes having different
informativeness, minus the 1 group of individuals with neither haplotype being
imputed well. Within each group, we calculate the ratio of the number of controls
and the number of cases, and choose the largest integer C that was less than this ratio
in all the groups. For example, if in one group there are 10.3 times as many controls
as cases and if in all other groups this ratio was greater, then we would set C¼ 10
and, within each group, randomly select ten times as many controls as there are
cases. For the RCC study, we used C¼ 45.
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Inﬂation factor adjustment. To account for the relatedness and stratiﬁcation
within our case and control sample sets, we applied the method of genomic control
based on chip markers (Fig. 1). For the RCC GWAS, the correction factor based on
genomic control is 1.26.
Genomic annotation analysis. We carried out a search for overlaps between the
location of rs35252396 and predicted biological features. We retrieved data from
UCSC test browser (HG19 build 37)28, and inspected manually all feature tracks
relevant to kidney tissue and identiﬁed those features that overlapped with the
location of the variant. These are recognized draft quality data and were used as
reported without quality ﬁltering.
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